Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB-DYYB Cause Shock? 33 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Shock have been filed in association with INFLIXIMAB-DYYB (ZYMFENTRA). This represents 0.1% of all adverse event reports for INFLIXIMAB-DYYB.

33
Reports of Shock with INFLIXIMAB-DYYB
0.1%
of all INFLIXIMAB-DYYB reports
1
Deaths
11
Hospitalizations

How Dangerous Is Shock From INFLIXIMAB-DYYB?

Of the 33 reports, 1 (3.0%) resulted in death, 11 (33.3%) required hospitalization.

Is Shock Listed in the Official Label?

Yes, Shock is listed as a known adverse reaction in the official FDA drug label for INFLIXIMAB-DYYB.

What Other Side Effects Does INFLIXIMAB-DYYB Cause?

Off label use (14,256) Condition aggravated (10,275) Intentional product use issue (7,549) Inappropriate schedule of product administration (5,977) Arthralgia (4,615) Drug ineffective (3,112) Fatigue (3,111) Weight increased (2,848) Malaise (2,766) Weight decreased (2,703)

What Other Drugs Cause Shock?

AMLODIPINE (1,626) METFORMIN (1,626) ACETAMINOPHEN (439) IBUPROFEN (350) DEXAMETHASONE (349) METHOTREXATE (290) TACROLIMUS (290) PREDNISONE (279) METOPROLOL (270) QUETIAPINE (264)

Which INFLIXIMAB-DYYB Alternatives Have Lower Shock Risk?

INFLIXIMAB-DYYB vs INFLIXIMAB-QBTX INFLIXIMAB-DYYB vs INFLIXIMAB, RECOMBINANT INFLIXIMAB-DYYB vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B

Related Pages

INFLIXIMAB-DYYB Full Profile All Shock Reports All Drugs Causing Shock INFLIXIMAB-DYYB Demographics